Psychopharmacology

, Volume 219, Issue 1, pp 225–233

Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis

  • Benedicto Crespo-Facorro
  • Rocío Pérez-Iglesias
  • Ignacio Mata
  • Obdulia Martínez-Garcia
  • Victor Ortiz
  • Jose Maria Pelayo-Terán
  • Elsa Valdizan
  • José Luis Vazquez-Barquero
Original Investigation

Abstract

Rationale

To enhance the effectiveness of antipsychotics in first-episode psychosis is crucial in order to achieve the most favourable prognosis. Difference in effectiveness between antipsychotics is still under debate.

Objective

The purpose of this study is to determine the long-term (3-year) effectiveness and efficacy of haloperidol, risperidone and olanzapine in first-episode schizophrenia-spectrum disorders.

Method

This is a prospective, randomized, open-label study. Data for the present investigation were obtained from a large epidemiologic and 3-year longitudinal intervention programme of first-episode psychosis. One hundred seventy-four patients were randomly assigned to haloperidol (N = 56), olanzapine (N = 55), or risperidone (N = 63) and followed up for 3 years. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on per-protocol populations was conducted in the analysis for clinical efficacy.

Results

The treatment discontinuation rate for any cause differed significantly between treatment groups (χ2 = 10.752; p = 0.005), with a higher rate in haloperidol than in risperidone and olanzapine. The difference in the discontinuation rate between risperidone and olanzapine showed a tendency towards significance (χ2 = 3.022; p = 0.082). There was a significant difference in the mean time to all-cause discontinuation between groups (log-rank χ2 = 12.657;df = 2; p = 0.002). There were no significant advantages to any of the three treatments in reducing the psychopathology severity.

Conclusions

After 3 years of treatment, a lower effectiveness was observed in haloperidol compared to second-generation antipsychotics (SGAs). The use of SGAs for the treatment of early phases of nonaffective psychosis may enhance the effectiveness of antipsychotics.

Keywords

Antipsychotics Schizophrenia Treatment Efficacy Clinical practice 

Supplementary material

213_2011_2392_MOESM1_ESM.doc (106 kb)
ESM 1(DOC 106 kb)

References

  1. Addington D, Addington J, Malika-tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry (Suppl) 22:39–44Google Scholar
  2. Andreasen NC (1983) Scale for the Assessment of Negative symptoms (SANS). University of Iowa, Iowa CityGoogle Scholar
  3. Andreasen NC (1984) Scale for the Assessment of Positive symptoms (SAPS). University of Iowa, Iowa CityGoogle Scholar
  4. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedCrossRefGoogle Scholar
  5. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla ML et al (2006) A practical clinical trial comparing haloperidol, risperidone and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 67:1511–1521PubMedCrossRefGoogle Scholar
  6. Crespo-Facorro B, Perez-Iglesias R, Mata I et al (2011) Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J Psychopharmacol 25:744–754PubMedCrossRefGoogle Scholar
  7. First MB, Spitzer RL, Gibbon M, William JB (2001) Structured Clinical Interview for DSM-IV-TR Axis I Disorders—non-patient edition. Biometrics Research Department, New YorkGoogle Scholar
  8. Gaebel W, Riesbeck M, Wölwer W et al (2007) Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68:1763–1774PubMedCrossRefGoogle Scholar
  9. Green AI, Lieberman JA, Hamer RM et al (2006) Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86:234–243PubMedCrossRefGoogle Scholar
  10. Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Department of Health, Education, and Welfare publication ADM 76338. National Institute of Mental Health, Washington, DC, pp 217–222Google Scholar
  11. Haro JM, Novick D, Suarez D et al (2009) Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res 43:265–273PubMedCrossRefGoogle Scholar
  12. Janca A, Kastrup M, Katschnig H et al (1996) The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatry Psychiatr Epidemiol 31:349–354PubMedCrossRefGoogle Scholar
  13. Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097PubMedCrossRefGoogle Scholar
  14. Kelly DL, Conley RR, Carpenter WT (2005) First-episode schizophrenia. A focus on pharmacological treatment and safety considerations. Drugs 65:1113–1138PubMedCrossRefGoogle Scholar
  15. Leucht S, Arbter D, Engel RR et al (2009a) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447PubMedCrossRefGoogle Scholar
  16. Leucht S, Corves C, Arbter D et al (2009b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMedCrossRefGoogle Scholar
  17. Lieberman JA (1996) Atypical antipsychotics drugs as a first-line treatment of schizophrenia: rationale and hypothesis. J Clin Psychiatry (Suppl) 11:68–71Google Scholar
  18. Lieberman JA, Tollefson G, Tohen M et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRefGoogle Scholar
  19. Lingjarde O, Ahlfors UG, Bech P et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and cross sectional study of side effects in antipsychotic-treated patients. Acta Psychiatr Scand (Suppl) 334:1–100CrossRefGoogle Scholar
  20. March JS, Silva SG, Compton S et al (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162:836–846PubMedCrossRefGoogle Scholar
  21. McEvoy JP, Lieberman JA, Perkins DO et al (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060PubMedCrossRefGoogle Scholar
  22. Miller IW, Bishop S, Norman WH et al (1985) The modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 14:131–142PubMedCrossRefGoogle Scholar
  23. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812Google Scholar
  24. Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M et al (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the PAFIP. Early Interv Psychiatry 2:178–187PubMedCrossRefGoogle Scholar
  25. Schooler N, Rabinowitz J, Davidson M et al (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. Am J Psychiatry 162:947–953PubMedCrossRefGoogle Scholar
  26. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl) 212:11–19CrossRefGoogle Scholar
  27. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325–351PubMedGoogle Scholar
  28. Young RC, Biggs JT, Ziegler VE et al (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–433PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Benedicto Crespo-Facorro
    • 1
    • 2
  • Rocío Pérez-Iglesias
    • 1
    • 2
  • Ignacio Mata
    • 1
    • 2
  • Obdulia Martínez-Garcia
    • 1
    • 2
  • Victor Ortiz
    • 1
  • Jose Maria Pelayo-Terán
    • 1
  • Elsa Valdizan
    • 2
    • 3
  • José Luis Vazquez-Barquero
    • 1
    • 2
  1. 1.University Hospital Marqués de Valdecilla, IFIMAV, Department of Psychiatry, School of MedicineUniversity of CantabriaSantanderSpain
  2. 2.CIBERSAM, Centro Investigación Biomédica en Red Salud MentalMadridSpain
  3. 3.Department of Physiology and Pharmacology and IBBTEC (UC-CSIC-SODERCAN)University of CantabriaCantabriaSpain

Personalised recommendations